Discussion  by unknown
animals. Examining the osmolarity values on bypass reveals
that no changes in osmolarity occur during bypass, indicat-
ing that prime osmolarity is not influential. This suggests
that postbypass fluid resuscitation of the fetus with isotonic
solutions, but not hypotonic solutions, would be preferable.
In summary, our results suggest that fluid shift in fetal car-
diac surgery with bypass is substantial and begins early dur-
ing bypass but is treatable with vigilant and appropriate fluid
resuscitation during the postbypass period. As such, it is
conceivable that some of the detrimental aspects of fetal by-
pass in prior studies might have been related to the manage-
ment of the fetus before, during, and after bypass (and
management of the fetal stress response) rather than directly
to the effects of exposure to extracorporeal circulation. Min-
iaturization of extracorporeal circuit volume is a necessary
engineering achievement likely to reduce inflammatory
stimuli and should enhance successful fetal bypass, particu-
larly if an oxygenator is used. However, current miniaturized
systems are closed systems and severely limit flexibility
during bypass. Our studies suggest that fluid resuscitation
therapy could potentially improve outcomes and prevent
the postbypass increase in PVR. Indeed, vigilant fluid resus-
citation can ameliorate or stave off the peripheral vasocon-
striction induced by hemoconcentration. Reduction of
these symptoms might ameliorate fetal circulatory centrali-
zation and subsequent placental dysfunction and multiorgan
failure.
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PDiscussion
Dr James S. Tweddell (Milwaukee, Wis). Thank you, Dr Eght-
esady. You and your colleagues are to be congratulated. That cer-
tainly is a complex animal model that you have chosen to tackle,
and your studies are very interesting.
You have identified and attempted to characterize placental dys-
function and fluid loss in these fetuses, and you have shown that
there are important fluid shifts. You have established that there is in-
travascular fluid loss of 0.8 mL $ kg1 $min1. This does not appear
in any of the major organs, and it does not appear in the placenta ei-
ther. You have concluded, correctly, I think, that placental edema
cannot be implicated as a mechanism of placental dysfunction.
My first question is this: Where do you think the fluid is going?
Dr Eghtesady. We are now starting to look at some other or-
gans, such as the skin, muscle, and gastrointestinal tract, specifi-
cally to see whether it is going there.ardiovascular Surgery c Volume 137, Number 3 721
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PDr Tweddell. Do you have anything you want to share with us
today?
Dr Eghtesady. We have a couple of animals in which there is
some suggestion that the gastrointestinal tract might be the culprit
site, but I think N of 2 is too small to make any conclusions.
Dr Tweddell. You have also measured vasopressin levels
throughout these studies, and others have implicated vasoconstric-
tors as part of the picture of placental dysfunction. In particular, 10
years ago, Frank Hanley demonstrated that products of cyclooxy-
genase might be important, possibly thromboxane or other prosta-
noids. If the production of these agents were blocked with
indomethacin, then the rate of placental dysfunction would be re-
duced. One of the stimuli for vasopressin release is osmolarity,
and you have shown quite nicely that it is probably not the case
here. What is the stimulus for vasopressin release in these fetuses?
Dr Eghtesady. You are absolutely right. We became interested
in this in part because of and building on the work of Dr Hanley and
others, who have shown that fetal stress can be very important in
terms of the evolution of placental dysfunction. Frankly, our dis-
covery of vasopressin was somewhat serendipitous. What I mean
by that is that we had previously looked at different stress response
markers, including b-endorphin, cortisol, and vasopressin, and the
impressive thing that we found was the increases in vasopressin
with fetal surgical bypass. Normally, vasopressin levels are approx-
imately 1 pg/mL in the fetal circulation, and with typical stress,
those levels go up to approximately 10 pg/mL. In our protocol
they increase to greater than 100 pg/mL. It just goes through the
roof. We have also seen that when the level exceeds 90 pg/mL,
those animals invariably do very poorly, whereas the animals that
mount a response that is appropriate but not excessive do well.
The exact mechanism of release of vasopressin in the fetus is still
not known. It is mediated by some effects from the pituitary gland,
but interestingly enough, the placenta and the umbilical cord are not
innervated. Therefore the mechanisms that actually regulate and
perhaps go back and tell the fetus to release this potent hormone,
which happens to be a powerful vasoconstrictor of placental vascu-
lature, are not totally clear to us, and that is one of the things that we
are looking into right now.
Dr Tweddell. Do you think it is a reduction in the atrial filling
pressures with the initiation of bypass, something as simple as that?
Dr Eghtesady. It is possible. But what is interesting, actually, in
the fetus is that we do not see a dramatic decrease in the filling pres-
sures. One of the things that has been impressive to me is that we
often talk about very little pulmonary blood flow in the fetus. Rou-
tinely we actually snare the pulmonary arteries because one of the
things that can happen is that you can have increased pulmonary
blood flow; although not on the percentage level of cardiac output,
it is still not huge. However, one of the things that is often not noted
in the literature that has been found to be very impressive is that
there is substantial aortopulmonary collaterals—or whatever you
want to call them—in terms of bronchial arteries that are equivalent
or greater in their volume of return back to the heart through these
other vessels. Therefore the heart does not completely empty out, as
we normally see in the bypass situation. You actually have to put
a vent separately into the left atrium, even though supposedly there
is a patent foramen ovale.722 The Journal of Thoracic and Cardiovascular SuTherefore I am not sure whether it is necessarily volume. Even
with a vacuum, when we have totally sucked the heart, we still
see the same vasopressin concentration. At this point, I do not
have any thoughts on what is exactly the mechanism.
Dr Tweddell. From amechanistic standpoint, the previous study
suggested that indomethacin might be helpful in this. Have you
considered using peripheral vasodilators, a-antagonists, or some-
thing of that nature? Is that in your future plans?
Dr Eghtesady. We have tried Regitine (phentolamine). We
have not tried phenoxybenzamine. We have tried Nipride (nitro-
prusside), milrinone, and dobutamine, and we are planning to use
some vasopressin antagonists that are now available.
Regitine does not work. For Nipride to work, the concentrations
you have to use are unbelievable. Normally, as you know, in the
clinical setting a half a microgram or maybe a microgram or 2. In
a fetus, to see a response to Nipride in this setting, you have to
go up to 10 to 15 mg $ kg1 $ min1. Milrinone has no effect what-
soever in the fetus.
Therefore of the things that we have tried thus far, we have not
had any success in terms of regulating that. That is why we are in-
terested in the vasopressin antagonist to see whether that works.
Dr Tweddell. Your study is one that could ultimately lead to
a clinical translation. Would you speculate for us on that? Assum-
ing you can get this to work, what would be some of the first lesions
you might tackle?
Dr Eghtesady. One of the ones that we were focusing on in the
laboratory is the intact atrial septum. I think when you see it in the
operating room, it is very clear how thick that is, and when it is truly
an intact septum, it is a challenge.When you look at the literature of
what our cardiology colleagues have tried to dowith stents and those
things, it has not been very effective, certainly in the fetus. Even in
the postnatal setting, often these kids that are coming out, and we
have had this algorithm of being prepared to help these fetuses
out, and they try to do a catheter-based approach to open up the sep-
tum. Invariably in the few cases that I have been involved in, it has
not been successful, and we had to start them on bypass and resect
the atrial septum. Therefore that is themodel onwhichwe have cho-
sen to focus. It is a fairly simple operation. In someways, to me, his-
torically, the very first operations in congenital heart surgery dealt
with the atrial septum. Therefore in a way we thought, ‘‘Let’s start
with that.’’ It is very simple and straightforward.
Dr Tweddell. That is terrific work, and you are to be congratu-
lated for developing this model and getting this underway.
Dr Frank W. Sellke (Boston, Mass). A lot is known about in-
flammatory stimuli in adult bypass, including the effects of neutro-
phils, complement, kinases, and so forth. Do you have any idea
what is going on in the fetus during bypass and then later reperfu-
sion?
Dr Eghtesady. A few studies have been done. We actually
recently got results from a sort of a pseudoproteomics approach
to try to look at this using a panel of antibodies from Kinexis.
Clearly, a number of inflammatory markers are increased. We
are currently digging our way through the data because there
are so many changes. We have noticed a pretty dramatic change
in some of the PKCs and we are trying to figure out what that
means.rgery c March 2009
